Faure-Conter Cécile, Pashankar Farzana
*Department of Pediatrics, Institut d'Hemato-Oncologie Pediatrique, Lyon, France †Yale University School of Medicine, New Haven, CT.
J Pediatr Hematol Oncol. 2017 Oct;39(7):487-489. doi: 10.1097/MPH.0000000000000950.
The question of giving or not adjuvant chemotherapy in pure ovarian immature teratomas (ITs) remains unsolved to date and illustrates differences in management between pediatric and adults oncologists. Because of the rarity of these tumors, this question has never been addressed through randomized trials. Standard of care for adult women with ovarian ITs is postoperative platinum based chemotherapy for all patients except FIGO stage IA, grade 1 tumors, whereas pediatric series concluded that surgery alone is curative for completely resected ovarian ITs, regardless of grade. Moreover the role of chemotherapy in incompletely resected tumors and its impact on the rate of malignant relapses needs to be better assessed. This emphasizes the urgent need for cooperation between adult and pediatric teams.
对于纯卵巢未成熟畸胎瘤（ITs）是否给予辅助化疗的问题至今仍未解决，这也体现了儿科肿瘤学家和成人肿瘤学家在治疗管理上的差异。由于这些肿瘤罕见，该问题从未通过随机试验得到解决。成年卵巢ITs女性患者的护理标准是，除FIGO分期为IA期、1级肿瘤外，所有患者术后均接受铂类化疗，而儿科系列研究得出结论，对于完全切除的卵巢ITs，无论分级如何，单纯手术即可治愈。此外，化疗在不完全切除肿瘤中的作用及其对恶性复发率的影响需要更好地评估。这凸显了成人和儿科团队之间迫切需要合作。
